Fisher & Paykel Healthcare Corporation Limited
FPH.AXHealthcareASXMedical Instruments & Supplies
Scan Results
Daily timeframeFisher & Paykel Healthcare Corporation Limited, together with its subsidiaries, designs, manufactures, markets, and sells medical device products and systems in North America, Europe, the Asia. The $18.43B market capitalization puts FPH.AX squarely in large-cap range for its industry. The company provides its products for use in acute and chronic respiratory care, and surgery, as well as the treatment of obstructive sleep apnea (OSA) in the home and hospital.
Market Cap
$18.43B
Beta
0.85
P/E (TTM)
48.28
P/E (Fwd)
35.66
EPS (TTM)
$0.65
EPS (Fwd)
$0.88
ROE
23.4%
ROA
14.7%
Cash
$461.1M
Total Debt
$146.1M
Free CF
$399.4M
52W Change
-8.5%
Annual Financials
Cash vs Debt
With $461.1M in cash and $146.1M in debt, FPH.AX maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Annual free cash flow of $399.4M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 23.4% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $1.64B to $2.31B.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Fisher & Paykel Healthcare Corporation Limited's trajectory.